SHR ‐2004, a Humanized Monoclonal Antibody Targeting Factor XI , for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active‐Controlled Phase 2 Study
SHR-2004, ein humanisierter monoklonaler Antikörper gegen Faktor XI, zur Vorbeugung venöser Thromboembolien nach Ovarialkarzinom-Operation: randomisierte, aktiv-kontrollierte Phase-2-Studie
American Journal of Hematology · 2026-11 · 101 (11) · 2776-2785
DOI: 10.1002/ajh.70481 ↗Auf einen Blick
SHR-2004 wurde nach Ovarialkarzinom-Operation mit Enoxaparin/Rivaroxaban verglichen. VTE traten unter SHR-2004 ähnlich häufig auf; schwere oder klinisch relevante nichtschwere Blutungen waren selten.
Fragestellung
Ist SHR-2004 zur Prävention von VTE nach Ovarialkarzinom-Operation wirksam und sicher im Vergleich zu Enoxaparin/Rivaroxaban?
Methode
Multizentrische, randomisierte, offene explorative Phase-2-Studie an 25 Zentren in China; 1:1-Zuteilung zu SHR-2004 oder Enoxaparin/Rivaroxaban; Beobachtung bis Tag 28.
Ergebnisse
198 Patient:innen erhielten die zugeteilte Behandlung (90 SHR-2004, 108 Enoxaparin/Rivaroxaban). Bei 181 mit Ultraschall: VTE 12,6 % vs. 20,2 %; Differenz −8,4 % (95 %-KI −19,9 bis 3,1). MB/CRNMB: 2,2 % vs. 1,9 %.
Einschränkungen
Explorative Phase-2-Studie; nur 181 Patient:innen mit protokollierter Ultraschallkontrolle; keine ausreichende Power für definitive Aussagen.
Schlussfolgerung der Autor:innen
SHR-2004 zeigte eine mit Enoxaparin/Rivaroxaban vergleichbare Wirksamkeit zur VTE-Prävention nach Ovarialkarzinom-Operation bei ähnlich niedrigem Blutungsrisiko.
Kernaussagen
- VTE bei 12,6 % unter SHR-2004 und 20,2 % unter Enoxaparin/Rivaroxaban
- Differenz −8,4 % (95 %-KI −19,9 bis 3,1)
- MB/CRNMB ähnlich selten: 2,2 % vs. 1,9 %
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, online erschienen am 26.08.2026. Verfasst von Guangyi Jiang und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Ovarian Neoplasms, Postoperative Complications, Venous Thromboembolism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
This multicenter, randomized, open‐label, exploratory Phase 2 trial assessed SHR‐2004, an anti‐FXI antibody, for venous thromboembolism (VTE) prevention in patients undergoing ovarian cancer surgery—a population at particularly high thrombotic risk conducted at 25 sites in China. Patients with newly diagnosed Stage III–IV or recurrent ovarian cancer scheduled for surgery were randomly assigned (1:1) to receive subcutaneous SHR‐2004 (180 mg on Day 1 and 120 mg on Day 15) or enoxaparin–rivaroxaban (subcutaneous enoxaparin 40 mg once daily during hospitalization, followed by oral rivaroxaban 10 mg once daily after discharge until Day 28). The primary efficacy outcome was the composite of VTE events within 28 days. The primary safety outcome was major bleeding (MB) or clinically relevant nonmajor bleeding (CRNMB) from first dose to 28 days. Between February 19, 2024 and September 17, 2024, 198 patients received assigned treatment (90 with SHR‐2004, 108 with enoxaparin–rivaroxaban) and were included in the safety analysis. Among 181 patients who completed protocol‐mandated ultrasonography, VTE occurred in 11 (12.6%) patients in the SHR‐2004 group and 19 (20.2%) in the enoxaparin–rivaroxaban group (difference −8.4%, 95% CI −19.9 to 3.1) by Day 28. MB/CRNMB rates were similar between groups (SHR‐2004: 2/90 [2.2%]; enoxaparin–rivaroxaban: 2/108 [1.9%]). In this study, SHR‐2004 showed comparable efficacy to enoxaparin–rivaroxaban for preventing postoperative VTE in patients undergoing ovarian cancer surgery, with a similar low risk of MB or CRNMB. The twice‐monthly dosing schedule offers a potential advantage over daily anticoagulation, supporting further investigation in adequately powered Phase 3 trials. Trial Registration: ClinicalTrials.gov identifier: NCT06220123
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
- Department of Gynecologic Oncology, Hunan Tumor Hospital, Changsha, China.
- Department of Gynecologic Oncology, Shanxi Provincial Cancer Hospital, Taiyuan, China.
- Department of Gynecologic Oncology, Jiangxi Cancer Hospital, Nanchang, China.
- Department of Gynecological Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
- Department of Gynecological Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
ORCID-Profile: Guangyi Jiang, Jie Tang, Keqiang Zhang, Jin Li, Ping Zhan, Jianqing Zhu
Förderung
- Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China
Zitieren
APA
Jiang, G., Tang, J., Zhao, H., Zhang, K., Gao, J., Yang, B., Wang, L., Yang, H., Chen, L., An, R., Zhang, H., Bu, H., Tang, J., Xu, X., Ruan, X., Xia, B., Wang, K., Wei, L., Sheng, X., …, & Zhu, J. (2026). SHR ‐2004, a Humanized Monoclonal Antibody Targeting Factor XI , for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active‐Controlled Phase 2 Study. American Journal of Hematology, 101(11), 2776-2785. https://doi.org/10.1002/ajh.70481
Vancouver
Jiang G, Tang J, Zhao H, Zhang K, Gao J, Yang B, et al. SHR ‐2004, a Humanized Monoclonal Antibody Targeting Factor XI , for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active‐Controlled Phase 2 Study. American Journal of Hematology. 2026;101(11):2776-2785. doi:10.1002/ajh.70481
BibTeX
@article{Jiang2026,
author = {Jiang, Guangyi and Tang, Jie and Zhao, Hongwei and Zhang, Keqiang and Gao, Jun and Yang, Bo and Wang, Li and Yang, Hongying and Chen, Liang and An, Ruifang and Zhang, Hui and Bu, Hualei and Tang, Junying and Xu, Xizhong and Ruan, Xiaohong and Xia, Bairong and Wang, Ke and Wei, Luwei and Sheng, Xiujie and Guo, Zhe and Chen, Lihong and Wang, Wei and Li, Jin and Wang, Danbo and Zhan, Ping and Guo, Yuhan and Wang, Yuqi and Dong, Yanli and Zhu, Jianqing},
title = {SHR ‐2004, a Humanized Monoclonal Antibody Targeting Factor XI , for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active‐Controlled Phase 2 Study},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {11},
pages = {2776--2785},
doi = {10.1002/ajh.70481}
}
EUVIMED